Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Abstract Background Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti–PD...

Full description

Bibliographic Details
Main Authors: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars, James L. Gulley
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Avelumab
PD-L1
Renal cell carcinoma
Metastatic
Phase I
Online Access:http://link.springer.com/article/10.1186/s40425-019-0746-2

Internet

http://link.springer.com/article/10.1186/s40425-019-0746-2

Similar Items